Abstract
L-glutamate is the major excitatory neurotransmitter in the central nervous system (CNS). Although just a few glutamate receptor ligands have turned out to be clinically useful, primarily because of unfavorable psychotropic side effects, the glutamate system remains an attractive molecular target in the treatment of epilepsy, neurodegenerative diseases (Alzheimers disease, Parkinsons disease, Huntingtons chorea), schizophrenia, ischemia, pain, alcoholism and mood disorders. Knowledge about the structure of ionotropic glutamate receptors (iGluRs) at atomic resolution is vital for the determination of their physiological and pathological importance and, thus, for drug design. Recently, tremendous progress has been made in structure elucidation and understanding of the functioning of iGluRs. The data about general topology and modular composition of iGluRs as well as numerous crystal structures of ligand binding domains of many iGluR subtypes has been supplemented with the first molecular models of the whole receptor protein, followed by the first crystal structures of N-terminal domains and finally by the first crystal structure of the whole tetrameric iGluR. This review summarizes experimental and computational efforts to determine iGluR molecular architecture and focus on the above listed achievements of the last years. In particular, the aspects of iGluR structure which are important for drug design, like the molecular characterstics of the ligand binding sites, are depicted in detail.
Keywords: NTD of ionotropic glutamate receptors, LBD of ionotropic glutamate receptors, glutamate ion channel, gating of glutamate ion channels, symmetry of ionotropic glutamate receptors
Current Medicinal Chemistry
Title: Molecular Structure of Ionotropic Glutamate Receptors
Volume: 17 Issue: 24
Author(s): A.A. Kaczor and D. Matosiuk
Affiliation:
Keywords: NTD of ionotropic glutamate receptors, LBD of ionotropic glutamate receptors, glutamate ion channel, gating of glutamate ion channels, symmetry of ionotropic glutamate receptors
Abstract: L-glutamate is the major excitatory neurotransmitter in the central nervous system (CNS). Although just a few glutamate receptor ligands have turned out to be clinically useful, primarily because of unfavorable psychotropic side effects, the glutamate system remains an attractive molecular target in the treatment of epilepsy, neurodegenerative diseases (Alzheimers disease, Parkinsons disease, Huntingtons chorea), schizophrenia, ischemia, pain, alcoholism and mood disorders. Knowledge about the structure of ionotropic glutamate receptors (iGluRs) at atomic resolution is vital for the determination of their physiological and pathological importance and, thus, for drug design. Recently, tremendous progress has been made in structure elucidation and understanding of the functioning of iGluRs. The data about general topology and modular composition of iGluRs as well as numerous crystal structures of ligand binding domains of many iGluR subtypes has been supplemented with the first molecular models of the whole receptor protein, followed by the first crystal structures of N-terminal domains and finally by the first crystal structure of the whole tetrameric iGluR. This review summarizes experimental and computational efforts to determine iGluR molecular architecture and focus on the above listed achievements of the last years. In particular, the aspects of iGluR structure which are important for drug design, like the molecular characterstics of the ligand binding sites, are depicted in detail.
Export Options
About this article
Cite this article as:
Kaczor A.A. and Matosiuk D., Molecular Structure of Ionotropic Glutamate Receptors, Current Medicinal Chemistry 2010; 17 (24) . https://dx.doi.org/10.2174/092986710791859379
DOI https://dx.doi.org/10.2174/092986710791859379 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Treatment of Estrogen Receptor-Positive Breast Cancer
Current Medicinal Chemistry GluN2B/N-methyl-D-aspartate Receptor Antagonists: Advances in Design, Synthesis, and Pharmacological Evaluation Studies
CNS & Neurological Disorders - Drug Targets Nitric Oxide Induced Damage and Preventive Effect of Curcumin and Quercetin on Buffalo Brain Cystatin
Current Proteomics Characterization of the Early CNS Stress Biomarkers and Profiles Associated with Neuropsychiatric Diseases
Current Genomics Neuropeptides as Therapeutic Targets to Combat Stress-Associated Behavioral and Neuroendocrinological Effects
CNS & Neurological Disorders - Drug Targets Gene Therapy, A Novel Therapeutic Tool for Neurological Disorders: Current Progress, Challenges and Future Prospective
Current Gene Therapy Amyloid-β Peptides, Alzheimer's Disease and the Blood-brain Barrier
Current Alzheimer Research Targeting Cancer and Neuropathy with Histone Deacetylase Inhibitors:Two Birds with One Stone?
Current Cancer Drug Targets Ultra-micronized Palmitoylethanolamide: An Efficacious Adjuvant Therapy for Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Emerging Signalling and Protein Interactions Mediated Via Metabotropic Glutamate Receptors
Current Drug Targets - CNS & Neurological Disorders Phytocannabinoids and Cannabimimetic Drugs: Recent Patents in Central Nervous System Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Nanoparticle Enabled Drug Delivery Across the Blood Brain Barrier: in vivo and in vitro Models, Opportunities and Challenges
Current Pharmaceutical Biotechnology Editorial (Thematic Issue: Role of Antioxidants Treatments on Oxidative Stress and Calcium Entry in Neurological Disease: Focus on TRP Channels)
Current Neuropharmacology Exploring the Role of Aggregated Proteomes in the Pathogenesis of Alzheimer’s Disease
Current Protein & Peptide Science Novel Therapeutic Effects of the Anti-Convulsant, Zonisamide, on Parkinsons Disease
Current Pharmaceutical Design Xenosensors CAR and PXR at Work: Impact on Statin Metabolism
Current Drug Metabolism Sao Paulo Research Conference on Molecular Medicine and Pharmacogenetics, A Joint Meeting with the IUPHAR Sub-Committee on Pharmacogenetics and the Brazilian Pharmacogenetics Network, Sao Paulo, Brazil, September 18-20, 2008
Current Pharmacogenomics and Personalized Medicine Allele Frequency Distributions of the Drug Metabolizer Genes <i>CYP2C9*2</i>, <i>CYP2C9*3</i>, and <i>CYP2C19*17</i> in the Buginese Population of Indonesia
Current Pharmacogenomics and Personalized Medicine PLGA Nanoparticles for Nose to Brain Delivery of Clonazepam: Formulation, Optimization by 32 Factorial Design, In Vitro and In Vivo Evaluation
Current Drug Delivery Antiepileptic Drugs (AEDs) Polypharmacy Could Lead to Buried Pharmacokinetic Interactions due to CYP450
Drug Metabolism Letters